Core Viewpoint - The article discusses the recent establishment of a merger and acquisition (M&A) fund by Reap Bio, highlighting the growing trend of companies participating in M&A funds as a strategic move to enhance their industry influence and operational synergy [2][3][5]. Group 1: Reap Bio's M&A Fund - On February 12, Reap Bio announced the signing of a partnership agreement to establish the Jiangsu Guotai Haitong Reap M&A Industry Fund, with a total scale of RMB 1 billion, where Reap Bio contributes RMB 295 million, accounting for 29.5% of the total [5][6]. - The fund's investment focus includes sectors related to Reap Bio's core business, such as animal health, synthetic biology, pets, and biomedicine, aiming to support the development of the real economy [5][6]. Group 2: Previous M&A Activities - This is not Reap Bio's first involvement as a limited partner (LP); in 2019, it invested RMB 200 million in the Tianjin Huapu Haihe Biomedicine Industry Fund, focusing on biomedicine and agricultural technology [7]. - In October of the previous year, Reap Bio contributed RMB 154 million to establish the Tianjin Baorui Equity Investment Partnership, which targets the pet industry [7]. Group 3: M&A Fund Market Trends - The article notes a significant increase in the establishment of M&A funds, with 305 listed companies participating in 321 funds in 2025, raising a total of RMB 297.51 billion, compared to 268 companies and 288 funds in 2024 [9]. - The M&A market is experiencing a surge in activity, driven by supportive policies and a growing appetite for industry consolidation, with notable transactions across various sectors [10][11]. Group 4: Future Outlook - The M&A market in China is projected to continue its growth, with a transaction volume exceeding USD 400 billion in 2025, marking a 47% year-on-year increase [11]. - The article emphasizes that the ongoing M&A wave is just beginning, with funds playing a crucial role in optimizing asset allocation and driving industry integration [13].

Core Insights - The poultry vaccine industry is crucial for preventing infectious diseases in poultry and is the foundation of modern poultry farming disease control [1] - China, as a major poultry producer and consumer, has a stable poultry production growth, which provides a solid demand base for the poultry vaccine market [1][8] - The market for poultry vaccines is expected to expand due to increased investment in disease prevention and a shift towards precision immunization models [1][9] Industry Overview - Poultry vaccines are biological agents developed specifically for birds such as chickens, ducks, and turkeys, aimed at inducing specific immune responses to prevent or control infectious diseases [2][3] - The poultry vaccine market can be categorized based on technology, pathogen type, usage characteristics, and vaccination methods [3][4] Market Dynamics - The Chinese poultry vaccine industry has a complete and interconnected supply chain, with high technical barriers in R&D and core raw material supply [5][6] - The demand is driven by government procurement of high-pathogenic avian influenza vaccines and market purchases from large farming groups and small farms [6][8] Policy Environment - The Chinese government has implemented strict management regulations to ensure the quality of veterinary biological products, including several guidelines and policies from 2022 to 2025 [6][7] - The mandatory immunization policy for major diseases has stabilized the vaccine coverage rate at over 98.7%, reinforcing the foundation for disease control in poultry [8] Market Growth Projections - The poultry meat production in China is projected to grow from 23.61 million tons in 2020 to 28.37 million tons by 2025, with a compound annual growth rate of 3.74% [9] - The poultry vaccine market is expected to recover and grow to 69.5 billion yuan in 2024, driven by increasing poultry output and vaccination demand [11][12] Vaccine Segmentation - The poultry vaccine market is primarily composed of inactivated vaccines, live vaccines, and other types, with inactivated vaccines holding over 65% market share [12] - The market for inactivated vaccines is projected to reach 4.65 billion yuan in 2024, while the segment for other vaccines, including genetically engineered and multivalent vaccines, is expected to grow significantly [12] Future Trends - The poultry vaccine industry is anticipated to achieve high-quality development driven by technological innovation, market consolidation, and demand upgrades [13] - Multi-valent vaccines will become the main focus of research and development, with new technologies like mRNA and viral vector vaccines accelerating commercialization [14] - The industry is expected to transition from a single vaccine supply model to a comprehensive service model that includes vaccines, diagnostics, and customized immunization plans [16]

Group 1 - Major shareholder Han Yuanfu of Dayuan Pump Industry plans to reduce his stake by up to 3%, totaling no more than 5.595 million shares [1] - Hainan Highway, a shareholder of Haikou Group, intends to increase its stake in the company by no less than 40 million yuan and no more than 50 million yuan [2] - China Communications Construction Company signed new contracts worth 1.883672 trillion yuan in 2025, a year-on-year increase of 0.13% [3] Group 2 - The controlling shareholder of Quzhou Development proposed to repurchase shares worth between 100 million and 200 million yuan [4] - Shareholder Huang Song of Huibo Pu plans to reduce his stake by up to 1%, totaling no more than 1.3372 million shares [5] - The board secretary of Fusenmei has had his detention lifted and is now under investigation, allowing him to resume his duties [6] Group 3 - YN Holdings clarified that its investment target does not belong to the sectors of computing chip manufacturing, computing leasing, or cloud services [7] - Shareholder Euro Star Diamond plans to reduce its stake in Laishen Tongling by up to 3%, totaling no more than 1.029 million shares [8] - Shareholder Zhu Guangkui of Demar Technology plans to reduce his stake by up to 3%, totaling no more than 791.24 million shares [10] Group 4 - Newnow's subsidiary received approval for clinical trials of drug SYS6023 for breast cancer treatment [11] - Ruipubio plans to invest 295 million yuan to establish a merger and acquisition industry fund focusing on animal health and biomedicine [12] - Shareholder Ningbo Hutong plans to reduce its stake in Huitong Energy by up to 1%, totaling no more than 206.28 million shares [13] Group 5 - Chengda Bio's high-dose influenza virus vaccine has received approval for clinical trials [14] - Kang En Bei's subsidiaries participated in the national centralized procurement process, with selected drugs expected to generate 385 million yuan in sales in 2024 [15] - Weitang Industrial signed a strategic cooperation framework agreement with Amphenol to enhance product development and market collaboration [16] Group 6 - Terui De is the first candidate for a 137 million yuan EPC general contracting project [17] - Chen Zhan Optoelectronics plans to invest 650 million yuan to establish an overseas smart manufacturing base [19] - Zhang Yi Technology's AI short drama business revenue is expected to account for no more than 1% of total revenue in 2025 [20] Group 7 - Jiangshan Co. plans to reduce its stake by up to 3%, totaling no more than 4.3308 million shares [21] - Xie Chuang Data plans to procure servers from multiple suppliers, with a total expected expenditure of no more than 11 billion yuan [22] - Huaming Equipment is planning to issue H-shares and list on the Hong Kong Stock Exchange [23] Group 8 - Wenzhou Hongfeng plans to raise no more than 450 million yuan through a private placement for expansion projects [24] - Yingkerui plans to raise no more than 379 million yuan for various projects including smart power supply systems [25] - Jingrui Electric Materials plans to invest 600 million yuan to build a key materials base for the integrated circuit manufacturing industry [26] Group 9 - Beijing Bank's chairman resigned due to age [27] - Youkeshu's actual controller plans to increase his stake by no less than 50 million yuan and no more than 100 million yuan [28] - Hanbo High-tech's subsidiary plans to acquire assets to enter the wet electronic chemicals industry [29] Group 10 - Jia Mei Packaging clarified that its capital operations related to Magic Atom will be independent of the listed company [30] - International Composite Materials confirmed that electronic-grade glass fiber is a key raw material for PCBs [31] - Zhongyin Fashion plans to procure hardware simulation accelerators for 9.385 million USD [32] Group 11 - Haohai Biotechnology's shareholder plans to reduce his stake by up to 0.4337% [33] - United Optoelectronics plans to sign a framework contract with Lingzhi Cloud Creation for robot assembly services [34] - Qianfang Technology's major shareholder plans to reduce its stake by up to 1.5%, totaling no more than 2.36507 million shares [35] Group 12 - Xiamen Airport plans to acquire 100% of Zhaoxiang Technology for 1.193 billion yuan [36] - Tuoshan Heavy Industry plans to acquire 51% of Xin Kaiyuan for 219 million yuan [38] - Shenkai Co. plans to repurchase shares worth between 40 million and 80 million yuan [39] Group 13 - Hushun Co. plans to invest 3.3 billion yuan in a high-end PCB production project [40] - Zhengzhou Bank appointed Wang Sentao as vice president, pending regulatory approval [41]

Core Viewpoint - The company, Reap Bio, addressed investor concerns regarding the impact of the tax rate increase on biological products from 3% to 13% starting January 1, 2026, stating that it will not affect the 2025 financial results but will lead to a short-term increase in actual tax burden in 2026 [1]. Summary by Categories Financial Impact - The company indicated that the new 13% tax rate will not influence the operating results for 2025, but there will be a short-term increase in tax burden once implemented in 2026 [1]. Strategic Response - Reap Bio plans to mitigate the impact of the tax rate adjustment through optimizing product pricing and structure, as well as improving supplier and procurement management [1]. Compliance and Value Creation - The company emphasized its commitment to strict tax compliance and effective management practices to create value for the company and its shareholders [1].

（文章来源：证券日报） 证券日报网讯 2月12日，瑞普生物发布公告称，持股5%以上股东梁武于2026年2月10日将280万股质押 给国金证券用于偿还债务，占其持股11.96%；同日解除质押430万股，占其持股18.37%。质押后梁武累 计质押880万股，占其持股37.60%。 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2026-004 瑞普生物股份有限公司 关于持股 5%以上股东梁武部分股份质押及解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 瑞普生物股份有限公司（以下简称"公司"）近日接到持股 5%以上股东梁 武先生的函告，获悉梁武先生所持有公司的部分股份办理了质押及解除质押手续， 具体事项如下： 一、股份质押的基本情况 | 是否为控 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 股股东或 本次质押 占其所 占公司 股东 | 是否 | 是否为 | | | | 质押 | | 第一大股 股份数量 持股份 总股本 名称 | 为限 | 补充质 | 质押起始日 | 质押到期日 | 质权人 | 用途 | | 东及一致 （股） 比例 比例 | 售股 | 押 | | | | | | 行动人 | | | | | | | | 梁武 否 2,800,000 11.96% 0.60% | 否 | 否 | 2026/02/10 | 2029/02/07 | ...

证券代码：300119 证券简称：瑞普生物 公告编号：2026-002 1、本次拟投资设立的合伙企业尚需办理工商登记和基金备案手续，具体实 施情况与进度尚存在不确定性。 2、并购产业基金具有周期长、流动性低的特性，本次投资可能面临回收期 较长、短期难以为公司贡献利润的风险。 3、本次投资还可能受宏观经济、行业周期、监管政策及标的公司经营管理 等多重因素影响，存在未能实现预期收益、无法及时有效退出甚至投资失败的风 险。 4、本次投资事项为关联方共同投资，不涉及同业竞争，不构成重大资产重 组。 一、概述 瑞普生物股份有限公司 关于与专业投资机构共同投资设立并购产业基金 暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 其他合作方海通并购资本、海通开元投资、高邮产业引导基金与公司及公司 控股股东、实际控制人、持股 5%以上的股东、董事、高级管理人员均不存在关 联关系或其他利益安排。截至本公告披露日，上述合作方未以直接或间接方式持 有公司股份。 瑞晟私募为公司董事长李守军先生、董事李睿女士间接控制的企业，李睿女 士担任瑞晟私募董事长、经理。 ...

瑞普生物股份有限公司 关于召开 2026 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、本次股东会召开的基本情况 1、股东会届次：2026年第一次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易 所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号——创 业板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章 程》的有关规定。 4、会议时间： 证券代码：300119 证券简称：瑞普生物 公告编号：2026-003 （1）现场会议时间：2026 年 3 月 3 日（星期二）14:30 （2）网络投票时间为：通过深圳证券交易所系统进行网络投票的具体时间 为 2026 年 3 月 3 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互 联网投票系统投票的具体时间为 2026 年 3 月 3 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 （1）现场投票：包括本人出席及 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2026-001 瑞普生物股份有限公司 第六届董事会第二次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、董事会会议召开情况 1 产业基金暨关联交易的公告》。 表决结果：同意 7 票，反对 0 票，弃权 0 票。 关联董事李守军、李睿在审议本议案时回避表决。 本议案已经公司第六届董事会战略委员会第一次会议及独立董事 2026 年第 一次专门会议审议通过，尚需提交公司 2026 年第一次临时股东会审议。 2、审议通过了《关于召开 2026 年第一次临时股东会的议案》 瑞普生物股份有限公司（以下简称"公司"）第六届董事会第二次（临时） 会议于 2026 年 2 月 12 日在公司会议室以现场结合通讯表决方式召开。会议通知 于 2026 年 2 月 9 日以书面及电子邮件等方式送达全体董事。公司应出席董事 9 人，实际出席董事 9 人（其中：独立董事王凯以通讯方式参会），参与表决董事 9 人。本次会议由董事长李守军先生主持，公司高级管理人员列席了会议。本次 会议的召集、召开和表决程序符合 ...

Core Viewpoint - Reap Bio (300119.SZ) aims to enhance its core strategy and expand its business boundaries and industry influence by establishing a partnership with several investment entities to create a new industrial fund focused on key sectors [1] Group 1: Partnership and Fund Establishment - Reap Bio signed a partnership agreement on February 12, 2026, with Haitong M&A (Shanghai) Private Equity Fund Management Co., Ltd., Haitong Kaiyuan Investment Co., Ltd., Gaoyou Industrial Guidance Fund (Limited Partnership), and Tianjin Ruisheng Private Fund Management Co., Ltd. [1] - The partnership will establish the Jiangsu Guotai Haitong Reap M&A Industrial Fund Partnership (Limited Partnership), which will focus on investments in animal health, synthetic biology, pets, and biomedicine [1] Group 2: Financial Commitment - The total subscribed capital for the partnership is set at RMB 1 billion, with Reap Bio contributing RMB 295 million, representing 29.50% of the total subscribed capital [1]